Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?

Ítems similars

• Tumor-associated macrophages—additional effectors at anti-PD-1/PD-L1 therapy?
  per: Suda, Kenichi
  Publicat: (2017)
• Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter
  per: Suda, Kenichi, et al.
  Publicat: (2016)
• Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
  per: Suda, Kenichi, et al.
  Publicat: (2019)
• Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer
  per: Saito, Yuichi, et al.
  Publicat: (2019)
• Non-invasive assessment of tumor PD-L1 status with circulating tumor cells
  per: Ulrich, Bryan C., et al.
  Publicat: (2018)